%D8%A2%D8%B2%D8%A7%D8%B3%DB%8C%D8%AA%DB%8C%D8%AF%DB%8C%D9%86Category:AzacitidineAzacytidinAzacitidinAzacitidineAzacitidina%D8%A2%D8%B2%D8%A7%D8%B3%DB%8C%D8%AA%DB%8C%D8%AF%DB%8C%D9%86AzacitidineAzacitidinAzacitidinaAzacitidin%C4%83%D0%90%D0%B7%D0%B0%D1%86%D0%B8%D1%82%D0%B8%D0%B4%D0%B8%D0%BDAzacitidinAzacitidinQ416451
about
P3781
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationA Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationGuadecitabine in Treating Patients With Higher-Risk Myelodysplastic SyndromesAzacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesStudy to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2Guadecitabine Extension StudyA Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerDurvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaEverolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaAzacytidine and Valproic Acid in Patients With Advanced CancersSIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic SyndromeDecitabine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCombination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesA Phase II Study of Maintenance With Azacitidine in MDS PatientsAzacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckDecitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous LeukemiaStudy of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)PRO#0118: Decitabine Plus Mini Flu-BuIn-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host DiseaseRomidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesMaintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapsePhase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMASGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer PatientsMRD-guided Treatment in NPM1mut AML PatientsDexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaAzacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaPevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AMLEnzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerA Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 MutationEnasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationDendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
P4844
Anti-oxidative and anti-inflammatory benefits of the ribonucleoside analogue 5-azacitidine in mice with acetaminophen-induced toxic hepatitis.Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.The opposed effect of 5-azacytidine and light on the development of reproductive structures in Neurospora crassa.Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes.BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes[Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine]Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid LeukaemiaA unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplantCDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidineAzacitidineStudy of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
P921
Q61862174-81AE4472-7E07-4578-8A06-D8E878113673Q61862214-F218C729-F093-44B8-A882-F062FB85D4D1Q61862232-030CBD51-1CDB-4159-96B3-4618455212D6Q61862273-7ECA2435-B9F8-49B5-A2BB-A95FC58ABA6AQ61894311-6BE5C9B0-D327-4392-9A4F-8ABB150744E2Q61894499-9986F218-73FF-431E-BE12-32E7914DD6D2Q61904981-250EBEC3-B0C2-4F17-B9FB-7964B855562CQ61905127-44B7D42D-DB77-4B98-884E-6712EEBDDD9FQ61907444-EF98D6A2-85EA-461F-9D79-5ADD5698C1B9Q61908775-52E6DB69-3A4A-4505-B1C3-AF50C8A53C35Q61909218-1C74F927-F4EF-4643-BE11-63E18375D0E1Q61915284-E3DBAD32-3F0D-4976-B7D3-3933992A1074Q61917487-4B53655E-9D5B-4E66-8F44-D2DB53B9D896Q61917558-6EB5B0EC-72A6-48B3-8A8E-7D2417A7C078Q61917893-88421078-D1EF-4F46-A0D6-3F64EB3C437BQ61920712-44ED565B-B41E-412E-9705-5BE4648F6B44Q61924449-04F12A47-BB92-4007-8BC6-1884D9A82BF1Q61924899-618E0C52-6FE4-45A3-9944-4EE93963CE53Q61936355-ECDF144A-CD87-47A9-B815-03A0F807F537Q61936869-889AA03C-1CA8-4219-8AF9-57E11D73D0ECQ61938394-CF5A6A18-0099-4631-8359-A07689C552B5Q61939162-4231B02E-F3FD-41D1-A34F-7AA818E0933DQ61939402-52EBED23-4F32-4BE3-93ED-4F7D119D7A61Q61957055-2AEC4238-3963-403B-BB03-F0A8B7BE202CQ61965699-1D36BE5A-74AF-48E4-9B82-DDAE6CB21EE8Q61966137-7BB71243-5DDE-48AC-8FAC-3A379DB4E111Q61966951-2E629248-3875-4AFE-AE04-B28F9A79269CQ61969478-CF78339D-CC0A-4CFD-802B-FE013BD7A5EAQ61969677-6AE6F119-3D8F-4C0D-A9E2-FB0511B5E89DQ61969843-45E1C6B4-CDBF-48C1-8D8A-A54314B7E587Q61975685-D10B5DBE-F32B-4CBC-8E7D-125AF0AE4D52Q61980115-C12FE04E-A05F-4A86-8DE8-E7B1035CC7D1Q62031463-F88E2C23-3071-45D3-8512-9C82D8897FFEQ62031790-FA16256E-E904-4C89-A49A-CE54CA882D37Q62040019-2548A479-53F8-4388-88A9-5C428CAD5DF1Q62042239-DB23766C-AFE3-4F3B-B7FE-7A34864EA029Q62042245-99E21630-4980-4A81-9B5F-978BE230BBE2Q62054628-41E31DE8-9E64-4FE6-B2B5-BD4AB85DA9E6Q62054737-4DB41AF1-C24C-4C44-BCF9-4FE6F26277DCQ62055048-881AC355-D92B-4E5D-9B10-15A059D54B6E
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Azacitidin
@de
Azacitidin
@hu
Azacitidin
@sh
Azacitidin
@sr
Azacitidine
@nl
Azacitidină
@ro
Azacytidin
@cs
azacitidin
@nn
azacitidina
@ca
azacitidina
@es
type
label
Azacitidin
@de
Azacitidin
@hu
Azacitidin
@sh
Azacitidin
@sr
Azacitidine
@nl
Azacitidină
@ro
Azacytidin
@cs
azacitidin
@nn
azacitidina
@ca
azacitidina
@es
altLabel
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
@en
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
@en
5 AZC
@en
5-AZAC
@en
5-Azacytidin
@de
5-Azacytidine
@en
5-aza
@fr
5-azacitidine
@fr
5-azacytidin
@cs
5-azacytidine
@en
prefLabel
Azacitidin
@de
Azacitidin
@hu
Azacitidin
@sh
Azacitidin
@sr
Azacitidine
@nl
Azacitidină
@ro
Azacytidin
@cs
azacitidin
@nn
azacitidina
@ca
azacitidina
@es